Evoke Pharma (NASDAQ:EVOK) Now Covered by StockNews.com

by · The Cerbat Gem

StockNews.com started coverage on shares of Evoke Pharma (NASDAQ:EVOK – Free Report) in a report released on Wednesday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Trading Down 2.1 %

NASDAQ EVOK opened at $4.37 on Wednesday. The company has a 50-day moving average price of $4.52 and a two-hundred day moving average price of $5.06. Evoke Pharma has a 52 week low of $3.54 and a 52 week high of $12.32. The stock has a market cap of $6.50 million, a price-to-earnings ratio of -0.40 and a beta of 0.15.

Institutional Trading of Evoke Pharma

An institutional investor recently bought a new position in Evoke Pharma stock. Corsair Capital Management L.P. purchased a new position in shares of Evoke Pharma, Inc. (NASDAQ:EVOK – Free Report) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned approximately 1.42% of Evoke Pharma at the end of the most recent quarter.

Evoke Pharma Company Profile

(Get Free Report)

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.

Further Reading